Vertex Pharmaceuticals Incorporated (LON:0QZU)

Market Cap	85.77B -6.3%
Revenue (ttm)	8.72B +10.3%
Net Income	2.73B
EPS	10.58
Shares Out	n/a
PE Ratio	31.37
Forward PE	22.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,371
Average Volume	2,054
Open	461.00
Previous Close	457.74
Day's Range	458.11 - 468.50
52-Week Range	362.50 - 519.68
Beta	0.32
RSI	47.95
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QZU

Financial Performance

Financial numbers in USD